• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

November 22, 2021

New Findings Link CRISPR Gene Editing and Mutated Cancer Cells

Author(s):

Aislinn Antrim, Managing Editor

The study’s identification of a network of possible candidate genes to carefully control for mutations could alter the future clinical implementation of CRISPR.

Because the p53 protein is activated during gene editing with the CRISPR technique, cells with this mutation have a survival advantage which can cause cancer, according to a recent study published in Cancer Research.

The CRISPR gene editing technique has significant potential in the future of precision medicine, according to a press release. However, the method has several significant hurdles before it can become widespread. One of these challenges involves cell behavior when subjected to DNA damage, which CRISPR gene editing causes. This damage activates the protein p53, which protects cells from damage.

Research had already established that the CRISPR technique is less effective with p53 is active, although a lack of p53 can also allow cells to grow uncontrollably and become cancerous. In more than half of all cancers, the gene for p53 is mutated and thus unable to protect against uncontrolled cell division. Therefore, it is essential to avoid the accumulation of such mutated cells.

In addition to these earlier findings, new research from the Karolinska Institutet has found that cells with inactivating mutations of the p53 gene gain a survival advantage when subjected to CRISPR and can therefore accumulate in a mixed cell population. The team also identified a network of linked genes with mutations that have a similar effect to p53 mutations and found that the transient inhibition of p53 is a potential pharmaceutical strategy for preventing the enrichment of cells with such mutations.

“It can seem contradictory to inhibit p53 in a CRISPR context,” said first author Long Jiang, a doctoral student at the Karolinska Institutet Department of Medicine, in the press release. “However, some of the literature supports the idea that p53 inhibition can make CRISPR more effective. In our study we show that this can also counteract the enrichment of cells with mutations in p53 and a group of associated genes.”

The study’s identification of a network of possible candidate genes to carefully control for mutations could alter the future clinical implementation of CRISPR. Another conclusion is that the transient inhibition of p53 could provide a strategy for reducing the enrichment of mutated cells, according to the press release.

The researchers have also investigated the DNA-damage response as a potential marker in the development of more precise guide RNA sequences, which show CRISPR where to alter a DNA sequence.

“We believe that the up-regulation of genes involved in the DNA damage response can be a sensitive marker for how much unspecific (‘off-target’) activity a guide RNA has, and can thus help in the selection of ‘safer’ guide RNAs,” said the study’s last author Fredrik Wermeling, a researcher at the Karolinska Institutet Department of Medicine, in the press release.

The next step for the research is to understand how relevant the described mechanisms are for the CRISPR technique and its implementation.

“In cell cultures, we see a rapid and pronounced enrichment of cells with p53 mutations when we subject the cells to CRISPR, provided, however, that cells with mutations are there from the start,” Wermeling said in the press release. “So we can show that the mechanism exists and factors that affect it, but don’t currently know at what level this is a genuine problem, and that’s something we want to explore further in more clinic-centered tests.”

REFERENCE

New findings on the link between CRISPR gene-editing and mutated cancer cells. News release. Karolinska Institutet; November 18, 2021. Accessed November 18, 2021. https://news.ki.se/new-findings-on-the-link-between-crispr-gene-editing-and-mutated-cancer-cells

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
OPC Pharmacy Times
Related Content
Advertisement
Mantle cell lymphoma -- Image credit: David A Litman | stock.adobe.com
June 27th 2025

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Ami Ali, PharmD, BCOP Mary Dzhuryan, PharmD Candidate Mehrnaz Razavi Vakhshoori, PharmD Candidate
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Health care professional prepping psilocybin -- Image credit: Microgen | stock.adobe.com
June 27th 2025

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Andrew Whitman, PharmD, BCOP
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Visualization of lungs with tumors | Image Credit: © Alexej - stock.adobe.com
June 25th 2025

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Alexandra Gerlach, Associate Editor
ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas
June 25th 2025

ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas

Jaume Capdevila, MD, PhD Alana Hippensteele, Lead Editor
Related Content
Advertisement
Mantle cell lymphoma -- Image credit: David A Litman | stock.adobe.com
June 27th 2025

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Ami Ali, PharmD, BCOP Mary Dzhuryan, PharmD Candidate Mehrnaz Razavi Vakhshoori, PharmD Candidate
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Health care professional prepping psilocybin -- Image credit: Microgen | stock.adobe.com
June 27th 2025

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Andrew Whitman, PharmD, BCOP
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Visualization of lungs with tumors | Image Credit: © Alexej - stock.adobe.com
June 25th 2025

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Alexandra Gerlach, Associate Editor
ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas
June 25th 2025

ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas

Jaume Capdevila, MD, PhD Alana Hippensteele, Lead Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.